Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXICURE, INC.XCUR · Entity 8068 | Director | June 13, 2022 | June 15, 2022 |
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | Director | June 19, 2019 | June 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXICURE, INC.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2032-06-12 | Direct | 50,000 |
Reported balance
After 2022-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date.
MOMENTA PHARMACEUTICALS INC
Report date June 19, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,090 |
Reported balance
After 2019-06-20 transaction · row 1
1 source rowRow 1 · 2019-06-20 · Exercise / conversion · Acquired 4,356 · Balance 54,090 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 25,000 |
Reported balance
After 2019-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-19 · Grant · Acquired 25,000 · Balance 25,000 F1: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-20 · Exercise / conversion · Disposed 4,356 · Balance 0 F2: Restricted Stock Units convert into common stock on a one-for-one basis. F3: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date.
F2: Restricted Stock Units convert into common stock on a one-for-one basis.
F3: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 35,090 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 317 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,800 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Arch Therapeutics, Inc.
Report date September 27, 2021 · Filed October 01, 2021
Section 16 reporting ended · disclosed 2021-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2031-09-26 | Direct | 250,000 |
Reported balance
After 2021-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-27 · Grant · Acquired 250,000 · Balance 250,000 F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2031-09-26 | Direct | 250,000 |
Reported balance
After 2021-09-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-27 · Grant · Acquired 250,000 · Balance 250,000 F2: The option was granted pursuant to the Plan. 1/3 of the option vested on the grant date and the remainder of the option shall vest equally on each of the first 24 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
F2: The option was granted pursuant to the Plan. 1/3 of the option vested on the grant date and the remainder of the option shall vest equally on each of the first 24 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
Keenova Therapeutics plc
Report date November 14, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-14 transaction · row 1
1 source rowRow 1 · 2023-11-14 · Disposition to issuer · Disposed 53,122 · Balance 0 F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland.
F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy.
F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2017 Filed May 22, 2017 19:14 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 10,110 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001179110-17-007792 · edgar.xml · derivative · entry 2 SULAT JAMES R · CIK 0001229448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 10,110 shares Expires 2027-05-18 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:14 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 4,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-007792 · edgar.xml · nonDerivative · entry 1 SULAT JAMES R · CIK 0001229448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,127 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 11:30 UTC | Arch Therapeutics, Inc. ARTH · Entity 109849 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001144204-17-006095 · v458451_4.xml · derivative · entry 2 SULAT JAMES R · CIK 0001229448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-02 F3 · derivative.exercise_date: Of the Shares subject to this Grant, 1/12th shall vest on each of the next twelve (12) monthly anniversaries of the vesting commencement date. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 11:30 UTC | Arch Therapeutics, Inc. ARTH · Entity 109849 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006095 · v458451_4.xml · nonDerivative · entry 1 SULAT JAMES R · CIK 0001229448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · security: Of the Shares subject to this grant, all are issued pursuant to the 2013 Stock Incentive Plan (the "Plan") and 100% shall fully vest on the second anniversary of the date of grant. In addition, in the event of a Change of Control (as such term is defined in the Plan) 100% of grant will immediately vest. F2 · balance_after: Excludes 838,934 shares owned by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's family are the beneficiaries. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.